Similarly, our own studies showed that GBM cells treated with c-MET inhibitor, crizotinib demonstrated an increase of PGC1A, resembling the findings observed with HDAC inhibitors and BRAF inhibitors [21]. The gene discussed is HDAC9; the disease is glioblastoma.